Biotage triples mRNA production equipment capacity

pharmafile | August 17, 2021 | News story | Manufacturing and Production  

Biotage has announced the expansion of its production capacity of large-scale flash columns, an element important for the production of mRNA vaccines, by 300%.

A new, bespoke production facility is now operational at the Biotage site in Cardiff, UK.

Anders Wikström, EVP Operations of Biotage, said: “Our customers needed to manufacture their products on a significantly larger scale, and we were able to invest in an expansion of our existing production facilities to support their requirements.

“We were very pleased to be able to deliver this expansion in just over four months in order to meet the needs of present and potential new clients.”

The availability of raw materials for mRNA vaccine production has been a major bottleneck as the lipids that were needed for new LNP (Lipid Nano Particles formulations used in mRNA vaccines) were not previously available on the scale needed to produce billions of doses of vaccine globally.

Tomas Blomquist, CEO and President of Biotage, said: “This initiative is an example of how Biotage has a positive impact on society in line with our ethos HumanKind Unlimited. At the same time, it proves that we have a keen ear to our customers’ needs and have built an organization capable of moving quickly to meet new demand in rapidly growing niche markets within the pharmaceutical industry.”

Kat Jenkins

Related Content

No items found

Latest content